Opportunities and challenges following approval of resmetirom for MASH liver disease

Jeffrey V. Lazarus, Dana Ivancovsky Wajcman, Henry E. Mark, Zobair M. Younossi, Christopher J. Kopka, Nevin Cohen, Meena B. Bansal, Michael Betel, Paul N. Brennan

Research output: Contribution to journalComment/Debate

Abstract

The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.

Original languageEnglish
JournalNature Medicine
Early online date19 Apr 2024
DOIs
StateE-pub ahead of print - 19 Apr 2024
Externally publishedYes

Bibliographical note

Publisher Copyright:
© Springer Nature America, Inc. 2024.

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Opportunities and challenges following approval of resmetirom for MASH liver disease'. Together they form a unique fingerprint.

Cite this